TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06441695

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: xumXR extended release caffeine
Description: proprietary capsule for extended release of caffeine
Study: NCT05503680

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: In this study, the researcher will provide participants with two month of Hatha yoga as an experimental intervention for managing stress. All participants who belong to the intervention group will be required to complete 120 minutes per week of home-based, online streaming yoga for eight weeks with our certified yoga instructor. The intervention will be conducted online by Zoom video; participants will be sent a link to join a scheduled live online yoga session twice every week. The data collection will be undertaken in three times: baseline (before the intervention begins), posttest one ( after two month intervention), and posttest two (one month after yoga intervention finish) to evaluate the lasting effect of yoga.
Study: NCT05098015

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Game Changers
Description: 8-session group intervention that uses didactic instruction, role plays and experience sharing to empower participants to engage in HIV prevention advocacy.
Study: NCT06231485

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEPS2
Description: One of the two health education curricula as described in arm/group descriptions.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: STYH
Description: One of the two health education curricula as described in arm/group descriptions.
Study: NCT04807179

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: RF Device Arm
Description: Non-invasive radiofrequency Alexandrite laser
Study: NCT05468203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg Tab
Description: Patients will be randomly assigned to receive either dapagliflozin 10 mg or placebo daily while in ICU for up to 30 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be randomly assigned to receive either dapagliflozin 10 mg or placebo daily while in ICU for up to 30 days
Study: NCT06175065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLS-0071
Description: RLS-0071, will be administered as an IV infusion 10 mg/kg. Planned infusion duration is 8 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control (commercial sterile saline), will be administered as an IV infusion. Planned infusion duration is 8 minutes.
Study: NCT05029999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLD Chemotherapy
Description: PLD chemotherapy will be administered 40 mg/m2 as intravenous injection once per cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLD Chemotherapy
Description: PLD chemotherapy will be administered 40 mg/m2 as intravenous injection once per cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-1140
Description: CDX-1140 will be administered 1.5mg/kg as intravenous injection once per cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-1140
Description: CDX-1140 will be administered 1.5mg/kg as intravenous injection once per cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-301
Description: CDX-301 will be administered 75µg/kg as subcutaneous injection daily x 5 doses per cycle for 2 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-301
Description: CDX-301 will be administered 75µg/kg as subcutaneous injection daily x 5 doses per cycle for 2 cycles.
Study: NCT05294523

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium priming dose
Description: Add the priming dose of rocuronium after the first supramaximal stimulation data measured

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium priming dose
Description: Add the priming dose of rocuronium after the first supramaximal stimulation data measured

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium priming dose
Description: Add the priming dose of rocuronium after the first supramaximal stimulation data measured
Study: NCT05238597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A197 Ophthalmic Solution
Description: A197 Ophthalmic Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A197 Ophthalmic Solution
Description: A197 Ophthalmic Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: A197 Vehicle Control
Description: A197 Vehicle Control

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Active Comparator
Study: NCT05280145

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EchOpen ultra-portable ultrasound device
Description: Depending on the clinical picture, the patient is examined with EchOpen to detect the presence or absence of pyelocaliceal dilatation or hepatic steatosis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound device routinely used in the department
Description: Patient who was first examined with EchOpen, is secondarily examined with an ultrasound probe used routinely in the department to detect pyelocaliceal dilatation or hepatic steatosis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound examination by an independent referent radiologist
Description: In a case of discordance between the assessments made with echOpen and the usual ultrasound device, an independent referent radiologist will use a standard ultrasound machine to constitute the gold standard (GS) rating. If the latter is not available to carry out the third ultrasound scan within a timeframe deemed clinically acceptable, then the evaluation will be carried out in a delayed manner, using the video loops and image captures saved during the two initial ultrasound scans.
Study: NCT05378529

Intervention type: OTHER
Group type: OTHER
Intervention: Lp(a) Screening
Description: Participants will provide demographic information and have a blood draw for Lp(a) levels if they are unknown.
Study: NCT05532657

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hearing intervention
Description: The hearing intervention is best practices hearing rehabilitation treatment program, consisting of fitting with hearing aids and other hearing assistive technologies along with comprehensive, individualized hearing rehabilitation sessions with a study audiologist spaced over the 2-3 months post-fitting designed to provide all the active components of the intervention. Participants also received semi-annual booster sessions with the study audiologist for 3 years and will continue to receive hearing healthcare from the study audiologist and complete semi-annual sessions for 3 additional years.
Study: NCT06441695

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: immediate release caffeine
Description: immediate release caffeine capsule
Study: NCT05917262

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based breathing
Description: The 20-minute mindfulness session is a scripted mindfulness exercise that incorporates mindfulness principles of intentionally paying attention to present-moment experiences in a non-judgmental fashion.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HRV biofeedback
Description: The 20-minute HRV biofeedback is based on the resonant frequency breathing with an external pacemaker. Generally, the breath rhythm is between 4.5 and 6.5 times per min.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive-behavioral pain psychoeducation
Description: The 20-minute psychoeducation session is a supportive session where behavioral coping strategies for pain management are discussed.
Study: NCT05532657

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Successful aging/delayed hearing intervention
Description: The successful aging health education program follows the protocol and materials developed for the 10 Keys to Healthy Aging program. The program involved individualized sessions with a study health educator, with initial sessions spaced over the 2-3 months post-randomization and semi-annual sessions for 3 years. Upon completion of the ACHIEVE trial, these participants are offered the best practices hearing rehabilitative treatment program with comprehensive, individualized sessions post-fitting and will receive semi-annual booster sessions with the study audiologist for 3 years.
Study: NCT05445323

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Low dose LX2006
Description: Adeno-associated viral vector encoding the FXN gene (AAVrh.10hFXN)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Mid Dose LX2006
Description: Adeno-associated viral vector encoding the FXN gene (AAVrh.10hFXN)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: High Dose LX2006
Description: Adeno-associated viral vector encoding the FXN gene (AAVrh.10hFXN)
Study: NCT04737603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ED-Initiated treatment with buprenorphine / naloxone
Description: A Clinical Opiate Withdrawal Score (COWS) score will be administered, and an induction dose of buprenorphine when COWS scores \>=8. Participants who weigh \> 70 kg and/or reported using ≥ 3 bags of heroin/day or its prescription opioid equivalent will receive 4 mg. After 1 hour an additional 4 mg will be administered for a total of 8 mg. Participants who weigh \<= 70 kg and/or reported using ≤ 3 bags of heroin/day or its prescription opioid equivalent will receive 4 mg of buprenorphine. After 1 hour, an additional 2 mg will be administered for a total of 6 mg. Patients will be prescribed sufficient take-home daily doses (one-week supply) to ensure that the patient has adequate medication to receive 12-16 mg buprenorphine sublingual once daily. Parents of adolescents will also receive appropriate education on how to administer medication. Home induction instructions will be provided to patients and parents that arrive to the ED after an opioid overdose.
Study: NCT06232252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765423
Description: BI 765423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765423
Description: BI 765423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765423
Description: BI 765423
Study: NCT05725343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Canakinumabwill be administered up to three years, or until lung cancer diagnosis, unacceptable toxicity or physician/subject's decision to withdraw, whichever comes first.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo will be administered up to three years, or until lung cancer diagnosis, unacceptable toxicity or physician/subject's decision to withdraw, whichever comes first.
Study: NCT06562725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: specific ventilator settings
Description: The special ventilator settings used in the intervention group - aimed at reducing airway pressure - include inspiratory flow \<25 L/min, tidal volume = 5m L/Kg, inspiratory time = 1 sec, respiratory frequency \<20 c/min, PEEP = 5 cmH2O, and FiO2 = 100%
Study: NCT05434442

Intervention type: OTHER
Group type: OTHER
Intervention: simulation model training
Description: Tracheal aspiration training of caregivers assigned to the simulation training group will be given to the same standard by researcher. It will be shown in practice on the tracheostomy care simulator.

Intervention type: OTHER
Group type: OTHER
Intervention: mobile app training
Description: An animation-based mobile application will be installed on the phones of the caregivers assigned to the mobile application group and will be introduced and made available to their use by the researcher.

Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: Clinical routine training will be given to caregivers in this group.

Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: Clinical routine training will be given to caregivers in this group.

Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: Clinical routine training will be given to caregivers in this group.
Study: NCT05590910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Fifteen minutes of classical music will be played overhead in the classroom. The students will be instructed not to use other electronic devices such as ear buds or phones during this time.
Study: NCT04861064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Participants will get Sirolimus (1.5-2 2mg/m2) weekly for 6 months.
Study: NCT04860128

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sports technology application
Description: Each of the intervention groups will use in after-school hours a different mobile app for 12 weeks, with a frequency and duration of 60 minutes of training, at least three times a week. A weekly record will be kept by the adolescents in which they will have to indicate the weekly practice frequency, the duration of the activity and the kilometers covered through a report that the adolescents will deliver to the teacher at the end of each week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sports technology application
Description: Each of the intervention groups will use in after-school hours a different mobile app for 12 weeks, with a frequency and duration of 60 minutes of training, at least three times a week. A weekly record will be kept by the adolescents in which they will have to indicate the weekly practice frequency, the duration of the activity and the kilometers covered through a report that the adolescents will deliver to the teacher at the end of each week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sports technology application
Description: Each of the intervention groups will use in after-school hours a different mobile app for 12 weeks, with a frequency and duration of 60 minutes of training, at least three times a week. A weekly record will be kept by the adolescents in which they will have to indicate the weekly practice frequency, the duration of the activity and the kilometers covered through a report that the adolescents will deliver to the teacher at the end of each week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sports technology application
Description: Each of the intervention groups will use in after-school hours a different mobile app for 12 weeks, with a frequency and duration of 60 minutes of training, at least three times a week. A weekly record will be kept by the adolescents in which they will have to indicate the weekly practice frequency, the duration of the activity and the kilometers covered through a report that the adolescents will deliver to the teacher at the end of each week.
Study: NCT06232252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765423
Description: BI 765423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BI 765423
Description: Placebo matching BI 765423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BI 765423
Description: Placebo matching BI 765423
Study: NCT06422026

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: APCP I
Description: Each subject takes one active bottle per day for 24 weeks. Each bottle contains APCP 3 g.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: APCP II
Description: Each subject takes one active bottle per day for 24 weeks. Each bottle contains APCP 4 g.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each subject takes one active bottle per day for 24 weeks.
Study: NCT04651348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Humanized Monoclonal Antibody MIL95
Description: PART A :The patients confirming to the eligibility criteria will be assigned to the 4 dose groups (0.1mg/kg, 0.3mg/kg, 0.8mg/kg, 1.0mg/kg, respectively) based on the sequence of inclusion. Each patient will receive an intravenous infusion of MIL95 every week on Day 1 for a maximum of Twelve weeks.~PART B:One recommended dose as a priming dose will be selected from 4 dose groups(0.1mg/kg、0.3mg/kg、0.8mg/kg、1.0mg/kg) based on results of PART A. Each patient will receive a priming dose of MIL95 on Day 1 Cycle 1.The patients will be assigned to the 5 maintenance dose groups (3mg/kg, 10mg/kg, 20mg/kg, 30mg/kg, 45mg/kg, respectively) based on the sequence of inclusion. The maintenance dose was given on Day 8,15,22 Cycle 1 and on Day 1,8,15,22 Cycle 2+. Each cycle was 28 days.
Study: NCT04446234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Use medicine according to patients condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Use medicine according to patients condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: Use medicine according to patients condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amisulpride
Description: Use medicine according to patients condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Use medicine according to patients condition
Study: NCT06232252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BI 765423
Description: Placebo matching BI 765423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BI 765423
Description: Placebo matching BI 765423
Study: NCT06419036

Intervention type: DEVICE
Intervention: Pneumowave DC
Description: Pneumowave biosensor(s) will be used to collect data from chest +/- movement.
Study: NCT06554301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: empagliflozin in treatment pulmonary aerterial hypertension
Description: On the basis of background treatment, the experimental group was given 10 mg of empagliflozin tablets orally once a day for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo in treatment pulmonary aerterial hypertension
Description: On the basis of background treatment, the control group was given 10 mg of placebo tablets orally once a day for 12 weeks.
Study: NCT05859555

Intervention type: OTHER
Group type: OTHER
Intervention: Thematic quality circles - Deprescription
Description: Thematic quality circles on benzodiazepines and analogues with a pharmacist (practical cases)
Study: NCT05390190

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non ablative radiofrequency
Description: Device
Study: NCT04949971

Intervention type: BEHAVIORAL
Intervention: High volume group
Description: Thea High tidal volume of the exposed group was 10ml/kg ideal body weight
Study: NCT06496230

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowering Pregnant Women and People Receiving Medications for Opioid Use Disorder
Description: Two-pronged intervention model: 1) behavioral intervention utilizing interoceptive exposures and cognitive behavioral therapy for insomnia and, 2) mobile application that facilitates medication adherence.
Study: NCT05696782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive Durvalumab 1500 mg intravenously every two weeks for 60 minutes. Each treatment is called a cycle and lasts for four weeks (or 28 days).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the EORTC Core Quality of Life Questionnaire (EORTC QLQ-C30)
Description: Participants will be asked to answer all 30 items on the EORTC Core Quality of Life questionnaire (EORTC QLQ-C30). This patient-reported outcome measure is designed to measure cancer patients' physical, psychological and social functions. The measure can be completed using a paper form, by verbally providing answers to the study team, or by entering the answers online into REDCap using a computer or mobile device. The total time to complete the questionnaire is approximately 11 minutes (

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: COPD Assessment Test (CAT)
Description: Participants will be asked to answer all items on the COPD assessment test (8 items) and the patient-reported outcome measures designed to measure respiratory function. The measures can be completed using a paper form, by verbally providing answers to the study team, or by entering the answers online into REDCap using a computer or mobile device. The total time to complete the questionnaire is less than 5 minutes.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Modified Medical Research Council (mMRC) dyspnea scale
Description: Participants will be asked to answer the modified medical research council dyspnea scale (1 item), and the patient-reported outcome measures designed to measure respiratory function. The measures can be completed using a paper form, by verbally providing answers to the study team, or by entering the answers online into REDCap using a computer or mobile device. The total time to complete the questionnaire is less than 5 minutes.
Study: NCT04966585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole Delayed Release Oral Tablet
Description: Three 100mg delayed-release tablets twice a day on the first day, then three 100mg delayed-release tablets once a day, starting on the second day. Duration of therapy will be 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo Tablet
Description: Three matching placebo tablets twice a day on the first day, then three tablets once a day, starting on the second day. Duration of therapy will be 12 weeks.
Study: NCT06560307

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Enterra Therapy System
Description: The Enterra® Therapy System for gastric electrical stimulation (GES) is indicated for the treatment of chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology in patients aged 18 to 70 years.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enterra Therapy System
Description: The Enterra® Therapy System for gastric electrical stimulation (GES) is indicated for the treatment of chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology in patients aged 18 to 70 years.
Study: NCT06026696

Intervention type: OTHER
Intervention: follow-up
Description: Long term follow-up
Study: NCT05584631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin G
Description: Intravenous immune globulin G dosed based on the subjects's current dose received for the treatment of CIDP.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous immune globulin G
Description: Subcutaneous immune globulin G converted from the subject's current IVIG dose 1:1.
Study: NCT06240208

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inactivity
Description: Inactivity will be implemented as cessation of active commuting and all other structured exercise. Furthermore, steps will be reduced to a maximum of 1500 steps/day.
Study: NCT06313879

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: online education
Description: Description of hydrocephalus disease, treatment methods and ventriculoperitoneal shunt care training will be given.